HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inter Parfums

This article was originally published in The Rose Sheet

Executive Summary

Fragrance marketer will introduce fragrances and complementary products under the Van Cleef & Arpels brand name per a licensing agreement with the jewelry designer, Inter Parfums announces Oct. 4. The license will run for 12 years, and each party has the right to extend the term for five years on or before June 1, 2018 if certain sales targets are met, firm notes. The deal represents an important step in Inter Parfums development, according to Inter Parfums CEO Jean Madar. "We believe its growth potential will strengthen opportunities for expansion of our fragrance business in the high luxury segment," he says. Concurrently, Van Cleef & Arpels' most recent fragrance licensee, YSL Beaute, has signed an agreement for early termination of its contract with the jewelry brand, a move that will allow YSL to focus on core fragrances. Van Cleef & Arpels fragrances include First, Tsar and Van Cleef & Arpels...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS014265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel